- Home
- MPB vs REPL Comparison
MPB vs REPL Comparison
Compare MPB & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- REPL
- Stock Information
- Founded
- MPB 1868
- REPL 2015
- Country
- MPB United States
- REPL United States
- Employees
- MPB N/A
- REPL N/A
- Industry
- MPB Major Banks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- REPL Health Care
- Exchange
- MPB Nasdaq
- REPL Nasdaq
- Market Cap
- MPB 641.4M
- REPL 757.8M
- IPO Year
- MPB N/A
- REPL 2018
- Fundamental
- Price
- MPB $27.02
- REPL $3.15
- Analyst Decision
- MPB Buy
- REPL Buy
- Analyst Count
- MPB 2
- REPL 10
- Target Price
- MPB $36.00
- REPL $8.25
- AVG Volume (30 Days)
- MPB 119.4K
- REPL 9.2M
- Earning Date
- MPB 07-23-2025
- REPL 08-07-2025
- Dividend Yield
- MPB 2.99%
- REPL N/A
- EPS Growth
- MPB N/A
- REPL N/A
- EPS
- MPB 2.32
- REPL N/A
- Revenue
- MPB $191,454,000.00
- REPL N/A
- Revenue This Year
- MPB $24.31
- REPL N/A
- Revenue Next Year
- MPB $13.74
- REPL N/A
- P/E Ratio
- MPB $11.53
- REPL N/A
- Revenue Growth
- MPB 13.07
- REPL N/A
- 52 Week Low
- MPB $22.50
- REPL $2.68
- 52 Week High
- MPB $33.87
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- MPB 37.09
- REPL 24.82
- Support Level
- MPB $28.74
- REPL $2.68
- Resistance Level
- MPB $29.34
- REPL $3.85
- Average True Range (ATR)
- MPB 0.82
- REPL 0.80
- MACD
- MPB -0.31
- REPL -1.03
- Stochastic Oscillator
- MPB 14.57
- REPL 4.45
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.